A Cross-Sectional Survey Reveals Physicians’ Treatment Patterns in First-Line and Maintenance Therapy for la/mUC

Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

The overall survival benefit of erdafitinib supports molecular testing of FGFR in all patients with metastatic urothelial carcinoma, according to an expert from University Paris-Saclay in France.

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

The FDA requests additional data and a safety update regarding N-803 plus BCG as a treatment for patients with BCG-unresponsive non-muscle invasive bladder carcinoma.

An artificial intelligence-based model for detecting lymph node metastases appears to identify tumor micrometastases in bladder cancer that pathologists may miss while classifying patient results as negative.